Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dazodalibep Expands Horizons With Phase II Sjögren’s Syndrome Data

Executive Summary

A Phase II trial of the anti-CD40 drug, which Horizon Therapeutics acquired in early 2021, met its primary endpoint in Sj

You may also be interested in...



Amgen Lays Out Plans For Rare Disease Portfolio Growth

Amgen detailed plans for increasing sales of drugs acquired in its Horizon transaction and outlined growth opportunities in its R&D pipeline during a rare disease showcase. 

Horizon Scores In Second Round Of Sjögren’s Trial A Month After Amgen Buyout

The company announced positive results in the second population of its Phase II study of dazodalibep in patients with Sj

Horizon Makes The Case For An Ambitious $10Bn Sales Goal

The rare disease specialist held its first R&D day since acquiring Viela Bio and laid out the development strategy for four mid-stage drugs to drive long-term growth.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147056

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel